About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: SRNE
- Previous Close: $5.10
- 50 Day Moving Average: $5.43
- 200 Day Moving Average: $6.12
- 52-Week Range: $57,939,000.00 - $4.62
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.43
- P/E Growth: 0.00
- Market Cap: $295.49M
- Outstanding Shares: 57,939,000
- Beta: 1.62
- Net Margins: -1,324.35%
- Return on Equity: -66.87%
- Return on Assets: -23.45%
Companies Related to Sorrento Therapeutics:
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 1.99%
- Quick Ratio: 1.99%
What is Sorrento Therapeutics' stock symbol?
Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."
Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2017?
4 brokerages have issued 12-month price targets for Sorrento Therapeutics' shares. Their predictions range from $15.00 to $30.00. On average, they expect Sorrento Therapeutics' stock price to reach $18.75 in the next year.
Who owns Sorrento Therapeutics stock?
Sorrento Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Intellectus Partners LLC (2.00%), State Street Corp (0.89%), Franklin Resources Inc. (0.59%), Putnam Investments LLC (0.20%) and Commonwealth of Pennsylvania Public School Empls Retrmt SYS (0.17%). Company insiders that own Sorrento Therapeutics stock include Henry Ji, Jerome B Zeldis, Kevin Herde, Patrick Soon-Shiong and Yue Alexander Wu.
Who sold Sorrento Therapeutics stock? Who is selling Sorrento Therapeutics stock?
Sorrento Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC.
Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?
Sorrento Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Intellectus Partners LLC and State Street Corp. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Henry Ji, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu.
How do I buy Sorrento Therapeutics stock?
Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Sorrento Therapeutics stock cost?
One share of Sorrento Therapeutics stock can currently be purchased for approximately $5.10.